

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                                 |
|-----------------------|---------------------------------|
| <b>Name of entity</b> | Tryptamine Therapeutics Limited |
| <b>ABN</b>            | 78 163 765 991                  |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                      |
|----------------------------|----------------------|
| <b>Name of director</b>    | Chris Ntoumenopoulos |
| <b>Date of last notice</b> | 4 December 2024      |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| <b>Direct or indirect interest</b>                               | Indirect  |
|--|---|
| <b>Nature of indirect interest (including registered holder)</b> | (1) - (3) Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director)<br><br>(4) Christopher Ntoumenopoulos & Leo Ntoumenopoulos ATF The Ntoumenopoulos superannuation fund<br><br>(5) - (7) Sobol Capital Pty Ltd ATF Sobol Capital Trust (Sole Director)  |
| <b>Date of change</b>  | 16 January 2025   |
| <b>No. of securities held prior to change</b>                    | (1) 5,000,000 - ORDINARY FULLY PAID SHARES<br>(2) 18,903,780 - TRYP TRANS OPT @ \$0.027 EXP 3 YEARS REINSTATEMENT 24M ESC<br>(3) 2,892,800 - EMPOPT E @ \$0.0531 EXP 5Y REINST 24M ESC<br>(4) 1,250,000 - ORDINARY FULLY PAID SHARES<br>(5) 3,500,000 - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027<br>(6) 3,500,000 - Dir AGM24 Opt \$0.04 Vest 31/12/2026 Exp 31/12/2029<br>(7) 8,750,000 - Dir AGM24 Opt \$0.05 Vest 31/12/2027 Exp 31/12/2030 |
| <b>Class</b>   | (5) Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027   |
| <b>Number acquired</b>   | N/A   |

<sup>+</sup> See [chapter 19](#) for defined terms.

|  |   |
|--|---|
| <b>Number disposed</b>                     | (5) (3,500,000) - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027   |
| <b>Value/Consideration</b>                 | (5) N/A   |
| <b>No. of securities held after change</b> | (1) 5,000,000 - ORDINARY FULLY PAID SHARES<br>(2) 18,903,780 - TRYP TRANS OPT @ \$0.027 EXP 3 YEARS REINSTATEMENT 24M ESC<br>(3) 2,892,800 - EMPOPT E @ \$0.0531 EXP 5Y REINST 24M ESC<br>(4) 1,250,000 - ORDINARY FULLY PAID SHARES<br>(5) 0 - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027<br>(6) 3,500,000 - Dir AGM24 Opt \$0.04 Vest 31/12/2026 Exp 31/12/2029<br>(7) 8,750,000 - Dir AGM24 Opt \$0.05 Vest 31/12/2027 Exp 31/12/2030 |
| <b>Nature of change</b>                    | (5) Lapsed Director Options incapable of meeting vesting conditions as at 31/12/2024  |

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | N/A |
| <b>Nature of interest</b>  | N/A |
| <b>Name of registered holder (if issued securities)</b>                      | N/A |
| <b>Date of change</b>  | N/A |
| <b>No. and class of securities to which interest related prior to change</b> | N/A |
| <b>Interest acquired</b>   | N/A |
| <b>Interest disposed</b>   | N/A |
| <b>Value/Consideration</b>   | N/A |
| <b>Interest after change</b>   | N/A |

## Part 3 - <sup>†</sup>Closed period

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>†</sup>closed period where prior written clearance was required?</b> | NO  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

<sup>†</sup> See [chapter 19](#) for defined terms.